Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-3914-8171
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.85 billion
Profitability
Miscellaneous
Employees42,535
Next Earnings Date11/7/2019 (Confirmed)
OptionableOptionable
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) posted its quarterly earnings results on Wednesday, August, 7th. The company reported $0.57 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.02. The business earned $4.34 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. Teva Pharmaceutical Industries's revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 earnings per share. View Teva Pharmaceutical Industries' Earnings History.
When is Teva Pharmaceutical Industries' next earnings date?
How can I listen to Teva Pharmaceutical Industries' earnings call?
Teva Pharmaceutical Industries will be holding an earnings conference call on Thursday, November 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?
Teva Pharmaceutical Industries issued an update on its FY19 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of $2.20-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $17.0-17.4 billion, compared to the consensus revenue estimate of $17.16 billion.
What price target have analysts set for TEVA?
24 equities research analysts have issued 12-month target prices for Teva Pharmaceutical Industries' stock. Their predictions range from $6.00 to $20.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $10.59 in the next year. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.
What is the consensus analysts' recommendation for Teva Pharmaceutical Industries?
24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 5 sell ratings, 13 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.
What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
- 1. According to Zacks Investment Research, "Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business and a massive debt load. Teva expects 2019 to be a tough year followed by return to growth in 2020 based on new launches. Its newest drugs, Austedo and Ajovy could emerge as significant contributors to long-term sales growth. However, despite impressive progress on restructuring activities, signs of stabilization in U.S. generic business and a more stable financial position than before, we believe the company has a long way to go before it gains stability. Resumption of organic growth seems unlikely until 2020. Teva’s shares have underperformed the generic industry this year so far. Estimates have gone down slightly ahead of Q1 earnings release. Teva has a mixed record of earnings surprises." (4/23/2019)
- 2. Maxim Group analysts commented, "Teva reported 3Q18 with revenues of $4.53B vs. $4.55B consensus and beat on the bottom line with non-GAAP EPS of $0.68 vs. $0.55. The beat was driven by positive impacts from the ongoing restructuring strategy with a spend base reduction of $2B YTD compared to 2017 (excluding FX) and on track to reach $3B by YE19." (11/1/2018)
Has Teva Pharmaceutical Industries been receiving favorable news coverage?
Headlines about TEVA stock have trended very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Teva Pharmaceutical Industries.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF) and GALAPAGOS NV/S (GLPG).
What other stocks do shareholders of Teva Pharmaceutical Industries own?
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
- Mr. Michael McClellan, Exec. VP & CFO (Age 48)
- Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
- Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
- Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)
Who are Teva Pharmaceutical Industries' major shareholders?
Teva Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Commerzbank Aktiengesellschaft FI (0.80%), Strs Ohio (0.14%), Zurcher Kantonalbank Zurich Cantonalbank (0.03%), SOL Capital Management CO (0.01%), Heritage Investors Management Corp (0.01%) and Wedbush Securities Inc. (0.00%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Which major investors are selling Teva Pharmaceutical Industries stock?
TEVA stock was sold by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, Strs Ohio, SOL Capital Management CO, Hanson & Doremus Investment Management, Heritage Investors Management Corp, NuWave Investment Management LLC, World Asset Management Inc and Nwam LLC. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Luzich Partners Llc, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Which major investors are buying Teva Pharmaceutical Industries stock?
TEVA stock was acquired by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Zurcher Kantonalbank Zurich Cantonalbank , Envestnet Asset Management Inc., Wedbush Securities Inc., Dfpg Investments Inc., Prospera Financial Services Inc, Moors & Cabot Inc. and G&S Capital LLC. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy shares of Teva Pharmaceutical Industries?
Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of TEVA stock can currently be purchased for approximately $8.03.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $8.77 billion and generates $18.85 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.
What is Teva Pharmaceutical Industries' official website?
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (NYSE TEVA)
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe TEVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
